Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
No Nuc, No Boost
2009-016480-11Phase 2Active
- Sponsor
- Pierre Dellamonica
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of maraviroc, raltegravir, tenofovir and emtricitabine in Human immunodeficiency virus infection type 1, sponsored by Pierre Dellamonica. Primary endpoints: Virological failure at week 48 (intention-to-treat) and Virological efficacy at week 48 in patients who underwent simplification. Started Nov 2009; status: active.
02
Drugs
maravirocraltegravirtenofoviremtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-016480-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016480-11.